Verve Therapeutics(VERV) - 2024 Q2 - Quarterly Results

Exhibit 99.1 Verve Therapeutics Announces Pipeline Progress and Reports Second Quarter 2024 Financial Results Heart-2 clinical trial of VERVE-102 enrolling in the U.K. and Canada; Clinical Trial Application cleared in Australia Heart-2 and PCSK9 program data update planned for first half of 2025 Phase 1b clinical trial initiation for VERVE-201 on track for the second half of 2024 Cash, cash equivalents, and marketable securities of $575.9 million; cash runway into late 2026 BOSTON — August 8, 2024 — Verve T ...